Science & Innovation
At the cutting edge of drug delivery technology
For over three decades, our core focus has been the development of groundbreaking, patient-centered technologies designed to deliver therapies to individuals living with Parkinson's disease. Our commitment to innovation drives us to continuously explore new ways to improve the delivery and effectiveness of treatments, ensuring that patients receive the best possible care tailored to their unique needs.
To achieve this, we actively collaborate with specialist focus groups and leading healthcare professionals who bring valuable insights and expertise to our research and development efforts. We also provide substantial funding for clinical trials that test new therapies and treatment methods, aiming to advance the understanding and management of Parkinson’s disease. Furthermore, we invest in care initiatives that enhance treatment programs, ultimately aiming to significantly improve the quality of life for those affected by this condition.
We work with specialist focus groups, fund clinical trials and invest in care initiatives that optimise treatment programmes and improve quality of life.
Barclay Pharmaceuticals Laboratories is committed to developing non-oral drug therapies that are simple to use and make life easier for patients and carers. Our vast experience and deep knowledge of Parkinson’s disease has helped us to develop pioneering drug delivery systems.
We don’t do in-house discovery, but are constantly horizon-scanning – searching out new technologies wherever they might be. We often work with small companies and universities who might not be internationally-renowned, but are making great discoveries all the time.
We can then apply our years of experience in the field and leverage our relationships in the Parkinson’s community to invest in and facilitate next-generation therapies.
Outside of Parkinson’s disease, we are also evaluating market opportunities within the broader field of neurology and always exploring new ways to bring products to market.
Our upcoming projects involve the search for new formulations to deliver levodopa subcutaneously to prevent patients from“peaks and troughs” of drug levels and provide more continuous control over symptoms.